The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38: An Application of the Classification System From the Universal Definition of Myocardial Infarction
Open accessAbstract
Background— Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI. Methods and Results— We studied 13 608 patients with acute coronary syndrome undergoing percutaneous coronary intervention randomized to prasugrel or clopidogrel and treated for 6 to 15 months in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). Each MI underwent supplemental classification as spontaneous, secondary, or sudden cardiac death (types 1, 2, and 3) or procedure related (Types 4 and 5) and examined events occurring early and after 30 days. Prasugrel significantly reduced the overall risk of MI (7.4% versus 9.7%; hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.67 to 0.85; P <0.0001). This benefit was present for procedure-related MIs (4.9% versus 6.4%; HR, 0.76; 95% CI, 0.66 to 0.88; P =0.0002) and nonprocedural (type 1, 2, or 3) MIs (2.8% versus 3.7%; HR, 0.72; 95% CI, 0.59 to 0.88; P =0.0013) and consistently across MI size, including MIs with a biomarker peak ≥5 times the reference limit (HR. 0.74; 95% CI, 0.64 to 0.86; P =0.0001). In landmark analyses starting at 30 days, patients treated with prasugrel had a lower risk of any MI (2.9% versus 3.7%; HR, 0.77; P =0.014), including nonprocedural MI (2.3% versus 3.1%; HR, 0.74; 95% CI, 0.60 to 0.92; P =0.0069). Conclusion— Treatment with prasugrel compared with clopidogrel for up to 15 months in patients with acute coronary syndrome undergoing percutaneous coronary intervention significantly reduces the risk of MIs that are procedure related and spontaneous and those that are small and large, including new MIs occurring during maintenance therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation
Cited by
Coronary Microembolization: From Bedside to Bench and Back to Bedside
Heusch, G., Kleinbongard, P., Böse, D., Levkau, B., Haude, M., Schulz, R., & Erbel, R. (2009) · Circulation · doi:10.1161/circulationaha.109.888784 · Cited by 419
Cuisset, T., Deharo, P., Quilici, J., Johnson, T. W., Deffarges, S., Bassez, C., Bonnet, G., Fourcade, L., Mouret, J. P., Lambert, M., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx175 · Cited by 414
Newby, L. K., Jesse, R. L., Babb, J. D., Christenson, R. H., De Fer, T. M., Diamond, G. A., Fesmire, F. M., Geraci, S. A., Gersh, B. J., Larsen, G. C., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.969 · Cited by 402
DeFilippis, A. P., Chapman, A. R., Mills, N. L., de Lemos, J. A., Arbab-Zadeh, A., Newby, L. K., & Morrow, D. A. (2019) · Circulation · doi:10.1161/circulationaha.119.040631 · Cited by 387
Self-citationLong-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury
Chapman, A. R., Shah, A. S. V., Lee, K. K., Anand, A., Francis, O., Adamson, P., McAllister, D. A., Strachan, F. E., Newby, D. E., & Mills, N. L. (2018) · Circulation · doi:10.1161/circulationaha.117.031806 · Cited by 362
Metadata
- Authors
- Morrow, D. A., Wiviott, S. D., White, H. D., Nicolau, J. C., Bramucci, E., Murphy, S. A., Bonaca, M. P., Ruff, C. T., Scirica, B. M., McCabe, C. H., Antman, E. M., & Braunwald, E.
- Venue
- Circulation
- Published
- 2009-06-02
- Volume
- 119
- Issue
- 21
- Pages
- 2758-2764
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2127324981
- Cited by
- 169
- References
- 1
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38: An Application of the Classification System From the Universal Definition of Myocardial Infarction. https://app.cochat.ai/papers/10.1161/circulationaha.108.833665
- The paper
- Morrow, D. A., Wiviott, S. D., White, H. D., Nicolau, J. C., Bramucci, E., Murphy, S. A., Bonaca, M. P., Ruff, C. T., Scirica, B. M., McCabe, C. H., Antman, E. M., & Braunwald, E. (2009). Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38: An Application of the Classification System From the Universal Definition of Myocardial Infarction. Circulation. https://doi.org/10.1161/circulationaha.108.833665
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.